scientists to grow everything from medicines to crops 
to materials, enabling ‘‘biology by design’’. 
(2) Biotechnology holds the potential for the 
United States to transform its military capabilities, 
strengthen food security and agricultural resilience, 
and cure life-threatening diseases, but it holds that 
same potential for other countries. The countries 
that master biotechnology first will gain the ability 
to shape how those technologies are used for decades 
to come. 
(3) Biotechnology unlocks the capabilities of 
producing medicines via biological systems, known as 
biopharmaceutical 
manufacturing. 
Biopharma-
ceutical manufacturing will enable better and less 
invasive treatments that extend and improve lives. 
(4) By investing in biomanufacturing, the 
United States Government would reduce dependency 
on foreign supply chains. 
(5) For United States manufacturers, the big-
gest roadblock to commercialization is proving that 
their products and processes can scale and produce 
a return on investment. Biomanufacturing requires 
flexible and affordable infrastructure for develop-
ment, to ensure that innovative products can rapidly 
move from the lab to commercial-scale production. 
VerDate Sep 11 2014 
02:20 Nov 19, 2025
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6089.IH
H6089
ssavage on LAPJG3WLY3PROD with BILLS
(b) SENSE OF CONGRESS.—It is the sense of Con-
gress that— 
(1) to realize the potential of biotechnology, the 
United States Government should establish a bio-
pharmaceutical manufacturing center of excellence; 
(2) the center should facilitate and accelerate 
manufacturing innovation, support good manufac-
turing practices, and provide for collaboration 
among public, private, and nonprofit institutions; 
and 
(3) the center should also facilitate training for 
workers to operate biotechnology tools and equip-
ment and to bolster talent throughout the bio-
technology sector. 
SEC. 
3. 
ESTABLISHMENT 
OF 
NATIONAL 
BIOPHARMA-
CEUTICAL CENTER OF EXCELLENCE. 
The National Institute of Standards and Technology 
Act (15 U.S.C. 271 et seq.) is amended— 
(1) by redesignating section 36 as section 37; 
and 
(2) by inserting after section 35 the following: 
‘‘SEC. 36. NATIONAL BIOPHARMACEUTICAL CENTER OF EX-
CELLENCE. 
‘‘(a) ESTABLISHMENT
OF
CENTER
OF
EXCEL-
LENCE.— 
VerDate Sep 11 2014 
02:20 Nov 19, 2025
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6089.IH
H6089
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(1) IN GENERAL.—The Director shall award a 
grant to or enter into an other transaction agree-
ment with, on a competitive basis, an eligible entity 
to establish and operate a center of excellence to be 
known as the National Biopharmaceutical Manufac-
turing Center of Excellence (in this section referred 
to as the ‘Center of Excellence’). 
‘‘(2) OBJECTIVES.—The objectives of the Cen-
ter of Excellence include— 
‘‘(A) advancing the science of biopharma-
ceutical manufacturing, especially with respect 
to products of particular importance to the na-
tional security, health security, or economic se-
curity of the United States, including by— 
‘‘(i) developing and demonstrating 
flexible biopharmaceutical manufacturing 
technologies and systems; 
‘‘(ii) improving upstream and down-
stream processes for multiple biopharma-
ceutical manufacturing platforms or prod-
uct modalities; 
‘‘(iii) 
improving 
biopharmaceutical 
manufacturing equipment and capabilities; 
and 
VerDate Sep 11 2014 
02:20 Nov 19, 2025
Jkt 069200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H6089.IH
H6089
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(iv) reducing supply bottlenecks and 
strengthening supply chain self-sufficiency 
through demonstration of innovative tech-
nologies; 
‘‘(B) supporting good manufacturing prac-
tices, quality by design, and standardization of 
chemistry, manufacturing, and controls to en-
sure effective and efficient manufacturing and 
to improve the regulation of innovative methods 
of manufacturing; 
‘‘(C) advancing workforce training and de-
velopment by working with educational and 
community partners to bolster biotechnology 
talent; 
‘‘(D) developing the science of and deploy-
ing the infrastructure for innovative biopharma-
ceutical manufacturing by engaging with— 
‘‘(i) institutions of higher education; 
‘‘(ii) small, medium, and large phar-
maceutical manufacturers; 
‘‘(iii) Federal, State, and local govern-
ment agencies and institutes; 
‘‘(iv) non-profit organizations; 
‘‘(v) professional organizations; and 
VerDate Sep 11 2014 
02:20 Nov 19, 2025
Jkt 069200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H6089.IH
H6089
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(vi) any other entity the Director 
considers relevant; 
‘‘(E) sharing with the head of any Execu-
tive agency that oversees the planning, manage-
ment, or coordination of Federal activities relat-
ing to biotechnology research generated by the 
Center of Excellence, including data regarding 
best practices for biopharmeceutical manufac-
turing; and 
‘‘(F) any other objective the Director con-
siders relevant. 
‘‘(3) FUNDING.—The Director shall award the 
Center of Excellence funding for any of the fol-
lowing: 
‘‘(A) To facilitate the construction of facili-
ties necessary to accomplish the objectives de-
scribed in paragraph (2). 
‘‘(B) To conduct collaborative research on 
new technology for scaling biopharmaceutical 
manufacturing in the United States for com-
mercial production. 
‘‘(C) To facilitate workforce training pro-
grams for biopharmaceutical manufacturing. 
VerDate Sep 11 2014 
02:20 Nov 19, 2025
Jkt 069200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H6089.IH
H6089
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(D) To fund relevant research and pro-
grams for the development of biopharmaceutical 
manufacturing. 
‘‘(b) APPLICATION; AWARD.— 
‘‘(1) IN GENERAL.—Not later than 180 days 
after the date of the enactment of this section, the 
Director shall solicit applications from eligible enti-
ties specified in paragraph (2) and award to or enter 
into with one such entity a grant or other trans-
action agreement to establish the Center of Excel-
lence. 
‘‘(2) ELIGIBILITY.—An entity is eligible to sub-
mit an application pursuant to paragraph (1) if— 
‘‘(A) the entity is— 
‘‘(i) a public-private partnership; 
‘‘(ii) an institution of higher edu-
cation; or 
‘‘(iii) a consortia of entities specified 
in clauses (i) or (ii); and 
‘‘(B) the entity is not a Federal entity. 
‘‘(3) CONTENT OF APPLICATION.—An applica-
tion submitted by an entity pursuant to paragraph 
(1) shall include— 
‘‘(A) examples from the entity of previous 
research, development, implementation, and 
VerDate Sep 11 2014 
02:20 Nov 19, 2025
Jkt 069200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H6089.IH
H6089
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(F) a description of any experience par-
ticipating in or leading biopharmaceutical man-
ufacturing partnerships, including those with 
institutions of higher education, pharmaceutical 
manufacturers, non-profit organizations, and 
governmental agencies— 
‘‘(i) to organize and conduct research 
and development aimed at— 
‘‘(I) creating and standardizing 
new and more effective technology; 
‘‘(II) developing best practices 
and sharing knowledge about such 
technology; 
‘‘(III) creating intellectual prop-
erty; and 
‘‘(IV) maintaining technological 
leadership in the United States; 
‘‘(ii) to support the deployment of in-
novative practices and infrastructure of 
biopharmaceutical manufacturing in the 
United States; and 
‘‘(iii) to support developing a skilled 
workforce ready to use innovations in the 
biopharmaceutical manufacturing sector; 
and 
VerDate Sep 11 2014 
02:20 Nov 19, 2025
Jkt 069200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H6089.IH
H6089
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(G) a description of how the entity in-
tends to utilize any funds authorized under this 
section to build or expand facilities and infra-
structure to achieve any of the objectives de-
scribed in subsection (a)(2). 
‘‘(4) SELECTION CRITERIA.—In selecting an ap-
plicant for a grant or other transaction agreement 
under paragraph (1), the Director shall consider the 
following: 
‘‘(A) The potential of the applicant to es-
tablish a Center of Excellence that would 
achieve the objectives set forth in subsection 
(a)(2). 
‘‘(B) The past performance of the appli-
cant in biopharmaceutical manufacturing work-
force development and the potential of the ap-
plicant to support workforce development activi-
ties in various regions throughout the United 
States. 
‘‘(C) The extent to which the applicant 
proposes to leverage the activities of other bio-
pharmaceutical manufacturing innovation, de-
velopment, and scaling initiatives. 
‘‘(D) Whether the proposed location for 
the Center of Excellence is proximate to other 
VerDate Sep 11 2014 
02:20 Nov 19, 2025
Jkt 069200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H6089.IH
H6089
ssavage on LAPJG3WLY3PROD with BILLS
biomanufacturing infrastructure, training facili-
ties, or industrial clusters. 
‘‘(E) The time the applicant estimates is 
needed for the Center of Excellence to be fully 
operational and to start delivering impact. 
‘‘(F) The amount of co-investment com-
mitted by Federal, State, private, and other 
sources to establish the Center of Excellence. 
‘‘(G) Any additional criteria that the Di-
rector considers relevant. 
‘‘(c) ANNUAL REPORTS.— 
‘‘(1) INITIAL REPORT.—Not later than one year 
after the date on which the Director awards to or 
enters into with an eligible entity a grant or other 
transaction agreement to establish the Center of Ex-
cellence under subsection (b)(1), the Director shall 
submit to Congress a report describing the progress 
on establishing the Center of Excellence, including— 
‘‘(A) the construction of facilities; 
‘‘(B) any activities, partnerships, and col-
laborations by the Center of Excellence; and 
‘‘(C) any other information regarding the 
formation of the Center of Excellence that the 
Director considers relevant. 
VerDate Sep 11 2014 
02:20 Nov 19, 2025
Jkt 069200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H6089.IH
H6089
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(2) PROGRESS REPORT.—Not later than one 
year after the date on which operations at the Cen-
ter of Excellence officially begin, the Director shall 
submit to Congress a report describing— 
‘‘(A) the activities, partnerships, collabora-
tions, and findings of the Center of Excellence; 
and 
‘‘(B) any other information regarding the 
Center of Excellence that the Director considers 
relevant. 
‘‘(3) FINAL REPORT.—Not later than 5 years 
after the date on which operations at the Center of 
Excellence officially begin, the Director shall submit 
to Congress a report describing— 
‘‘(A) the activities, partnerships, collabora-
tions, and findings of the Center of Excellence; 
and 
‘‘(B) any other information regarding the 
Center of Excellence that the Director considers 
relevant. 
‘‘(4) PUBLICATION.—The Director shall make 
the reports required by paragraphs (1), (2), and (3) 
available to the public in an easily accessible elec-
tronic format on a website of the Federal Govern-
ment that includes information on biotechnology. 
VerDate Sep 11 2014 
02:20 Nov 19, 2025
Jkt 069200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H6089.IH
H6089
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(d) INTELLECTUAL PROPERTY.—The Director shall 
ensure that, prior to commencing operations, the Center 
of Excellence, in consultation with similar existing institu-
tions, such as Manufacturing USA institutes (as defined 
in section 34(d)), establishes intellectual property guide-
lines for research conducted within or in collaboration with 
the Center of Excellence. 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to the Director to carry 
out this section $120,000,000 for fiscal year 2026. 
‘‘(f) DEFINITIONS.—In this section: 
‘‘(1) BIOMANUFACTURING.—The term ‘bio-
manufacturing’ means the application of bio-
technology to manufacturing. 
‘‘(2) BIOPHARMACEUTICAL.—The term ‘bio-
pharmaceutical’ means a pharmaceutical drug prod-
uct manufactured using, extracted from, or syn-
thesized from living cells or biological organisms. 
‘‘(3) 
BIOTECHNOLOGY.—The 
term 
‘bio-
technology’ means the application of science or engi-
neering, directly or indirectly, to— 
‘‘(A) a living organism; 
‘‘(B) a part or product of a living orga-
nism; or 
VerDate Sep 11 2014 
02:20 Nov 19, 2025
Jkt 069200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H6089.IH
H6089
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(C) a modified form of subparagraph (A) 
or (B). 
‘‘(4) EXECUTIVE AGENCY.—The term ‘Execu-
tive agency’— 
‘‘(A) has the meaning given that term in 
section 105 of title 5, United States Code; and 
‘‘(B) includes the Executive Office of the 
President and the Office of the Vice President. 
‘‘(5) INSTITUTION OF HIGHER EDUCATION.— 
The term ‘institution of higher education’ has the 
meaning given that term in section 101 of the High-
er Education Act of 1965 (20 U.S.C. 1001).’’. 
Æ 
VerDate Sep 11 2014 
02:20 Nov 19, 2025
Jkt 069200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6301
E:\BILLS\H6089.IH
H6089
ssavage on LAPJG3WLY3PROD with BILLS